Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filipa Lynce

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Therapeutic Advances in Medical Oncology|August 4, 2022
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancerSonia Pernas, Jennifer L Guerriero, Sergey Naumenko, et al.
Breast Cancer Research and Treatment|January 11, 2016
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclinesAna Barac, Filipa Lynce, Karen L Smith, et al.
Annals of Surgical Oncology|May 12, 2025
ASO Visual Abstract: Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy RatesAnna Weiss, Maria Sol Rosito, Danielle Braun, et al.
JAMA Oncology|March 21, 2024
PARP Inhibitors for Breast Cancer Treatment: A ReviewStefania Morganti, Antonio Marra, Carmine De Angelis, et al.
Annals of Surgical Oncology|March 20, 2025
Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy RatesAnna Weiss, Maria Sol Rosito, Danielle Braun, et al.
Translational Behavioral Medicine|January 25, 2023
Cultural adaptations to a telephone genetic counseling protocol and booklet for Latina breast cancer survivors at risk for hereditary breast and ovarian cancerSara Gómez-Trillos, Kristi D Graves, Katie Fiallos, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progressionHai P Nguyen, Rory Sheng, Elizabeth Murray, et al.
The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.
Future Oncology (London, England)|June 26, 2024
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancerSara M Tolaney, Angela DeMichele, Toshimi Takano, et al.
JCO Precision Oncology|December 7, 2023
Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next StepsKimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Therapeutic Advances in Medical Oncology|August 4, 2022
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancerSonia Pernas, Jennifer L Guerriero, Sergey Naumenko, et al.
Breast Cancer Research and Treatment|January 11, 2016
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclinesAna Barac, Filipa Lynce, Karen L Smith, et al.
Annals of Surgical Oncology|May 12, 2025
ASO Visual Abstract: Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy RatesAnna Weiss, Maria Sol Rosito, Danielle Braun, et al.
JAMA Oncology|March 21, 2024
PARP Inhibitors for Breast Cancer Treatment: A ReviewStefania Morganti, Antonio Marra, Carmine De Angelis, et al.
Annals of Surgical Oncology|March 20, 2025
Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy RatesAnna Weiss, Maria Sol Rosito, Danielle Braun, et al.
Translational Behavioral Medicine|January 25, 2023
Cultural adaptations to a telephone genetic counseling protocol and booklet for Latina breast cancer survivors at risk for hereditary breast and ovarian cancerSara Gómez-Trillos, Kristi D Graves, Katie Fiallos, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progressionHai P Nguyen, Rory Sheng, Elizabeth Murray, et al.
The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.
Future Oncology (London, England)|June 26, 2024
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancerSara M Tolaney, Angela DeMichele, Toshimi Takano, et al.
JCO Precision Oncology|December 7, 2023
Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next StepsKimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.
Pageof 10